Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Firocoxib SCHEMBL1383179 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4213329 | 0.84 | PTGS2 (0.85) | PTGS2PTGS1 | |
| SCHEMBL5203543 | 0.83 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL5205472 | 0.82 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5208636 | 0.81 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6957455 | 0.80 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL20289792 | 0.79 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL5210738 | 0.78 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL5204977 | 0.78 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL15714003 | 0.78 | PTGS2 (0.80) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263467-B1 | PASTE FORMULATIONS COMPRISING SILICA | MERIAL LTD (GB) | 2006-05-31 | — | — | EP | claimed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | claimed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | claimed |
| EP-1617822-A4 | TABLETS AND METHODS FOR MODIFIED RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS | YAMANOUCHI PHARMA TECH INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| EP-1617822-A2 | TABLETS AND METHODS FOR MODIFIED RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS | Yamanouchi Pharma Technologies, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1572166-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB, VALDECOXIB AND BENZOPYRAN DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1565169-A1 | DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB AND VALDECOXIB | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2001062251-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001045705-A1 | SUSTAINED-RELEASE FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045706-A1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2- INHIBITOR | PHARMACIA CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001041760-A2 | CYCLOOXYGENASE-2 INHIBITOR COMPOSITIONS HAVING RAPID ONSET OF THERAPEUTIC EFFECT | PHARMACIA CORPORATION (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0904269-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.